<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40375290</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Proteomic-based biomarker discovery reveals panels of diagnostic biomarkers for early identification of heart failure subtypes.</ArticleTitle><Pagination><StartPage>546</StartPage><MedlinePgn>546</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-025-06563-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Limited access to echocardiography can delay the diagnosis of suspected heart failure (HF), which in turn postpones the initiation of optimal guideline-directed medical therapy. Although natriuretic peptides like B-type natriuretic peptide (BNP) are valuable biomarkers for diagnosing and managing HF, the utility of combining BNP with other blood-based biomarkers to predict subtypes of new-onset HF remains underexplored.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This study sought to investigate and evaluate the diagnostic significance of adding blood-based biomarkers to BNP for identifying heart failure with preserved ejection fraction (HFpEF) or reduced ejection fraction (HFrEF), with the goal of enhancing diagnostic assays beyond BNP measurements.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We identified candidate blood protein biomarkers using untargeted proteomics workflows from a cohort of individuals recruited to the STOP-HF trial who were at risk of HF and subsequently developed either HFpEF or HFrEF over time ("HF progressors"; n&#x2009;=&#x2009;40). Candidate biomarkers were verified in an independent cohort (n&#x2009;=&#x2009;52) from a community-based rapid access HF diagnostic clinic. The biological processes associated with these proteins were assessed, and the diagnostic values of biomarker panels were evaluated using a machine learning approach.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Within HF progressors, we identified 3 proteins associated with HFpEF development: vascular cell adhesion protein 1 (VCAM1), insulin-like growth factor 2 (IGF2), and inter-alpha-trypsin inhibitor heavy chain 3 (ITIH3). Additionally, 4 proteins were linked to HFrEF development: C-reactive protein (CRP), interleukin-6 receptor subunit beta (IL6RB), phosphatidylinositol-glycan-specific phospholipase D (PHLD), and noelin (NOE1). These findings were verified in an independent cohort to distinguish HF subtypes from controls. Moreover, a random forest algorithm demonstrated that combining these candidate biomarkers with BNP measurement significantly improved the prediction of HF subtypes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We identified candidate proteins linked to HFpEF and HFrEF in a longitudinal HF progressor cohort and validated them in a community-based cohort. Adding these proteins to BNP led to a significant improvement in HF subtype prediction. Study results have clinical implications for blood-based screening of HF subtypes using panels of biomarkers, particularly in resource-limited settings.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karuna</LastName><ForeName>Narainrit</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tonry</LastName><ForeName>Claire</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ledwidge</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UCD Conway Institute and Research and Innovation Programme for Chronic Disease, School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>STOP-HF Unit, Department of Cardiology, St. Vincent's University Healthcare Group, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glezeva</LastName><ForeName>Nadezhda</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>UCD Conway Institute and Research and Innovation Programme for Chronic Disease, School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallagher</LastName><ForeName>Joe</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>UCD Conway Institute and Research and Innovation Programme for Chronic Disease, School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>STOP-HF Unit, Department of Cardiology, St. Vincent's University Healthcare Group, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>UCD Conway Institute and Research and Innovation Programme for Chronic Disease, School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>STOP-HF Unit, Department of Cardiology, St. Vincent's University Healthcare Group, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Chris J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0001-8749-0732</Identifier><AffiliationInfo><Affiliation>Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK. chris.watson@qub.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UCD Conway Institute and Research and Innovation Programme for Chronic Disease, School of Medicine, University College Dublin, Dublin, Ireland. chris.watson@qub.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>STOP-HF Unit, Department of Cardiology, St. Vincent's University Healthcare Group, Dublin, Ireland. chris.watson@qub.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>114471-18-0</RegistryNumber><NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="Y">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declarations. Disclosures: None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>16</Day><Hour>11</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>16</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>15</Day><Hour>23</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40375290</ArticleId><ArticleId IdType="doi">10.1186/s12967-025-06563-7</ArticleId><ArticleId IdType="pii">10.1186/s12967-025-06563-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Xanthakis V, Enserro DM, Larson MG, Wollert KC, Januzzi JL, Levy D, Aragam J, Benjamin EJ, Cheng S, Wang TJ, et al. Prevalence, neurohormonal correlates, and prognosis of heart failure stages in the community. JACC Heart Fail. 2016;4:808&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">27395350</ArticleId><ArticleId IdType="pmc">8450920</ArticleId><ArticleId IdType="doi">10.1016/j.jchf.2016.05.001</ArticleId></ArticleIdList></Reference><Reference><Citation>Young KA, Scott CG, Rodeheffer RJ, Chen HH. Progression of preclinical heart failure: a description of stage A and B heart failure in a community population. Circ Cardiovasc Qual Outcomes. 2021;14:e007216.</Citation><ArticleIdList><ArticleId IdType="pubmed">33951931</ArticleId><ArticleId IdType="pmc">8137558</ArticleId><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.120.007216</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118:3272&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">35150240</ArticleId><ArticleId IdType="doi">10.1093/cvr/cvac013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Gao C, Guignard-Duff M, Cole C, Hall C, Larman M, Baruah R, Gao H, Mamza J, Lang C. Importance of early diagnosis and treatment of heart failure across the spectrum of ejection fraction. Eur Heart J. 2023;44(ehad655):892.</Citation></Reference><Reference><Citation>Bayes-Genis A, Docherty KF, Petrie MC, Januzzi JL, Mueller C, Anderson L, Bozkurt B, Butler J, Chioncel O, Cleland JGF, et al. Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the Heart Failure Association of the ESC. Eur J Heart Fail. 2023;25:1891&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">37712339</ArticleId><ArticleId IdType="doi">10.1002/ejhf.3036</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohde LE, Beck-da-Silva L, Goldraich L, Grazziotin TC, Palombini DV, Polanczyk CA, Clausell N. Reliability and prognostic value of traditional signs and symptoms in outpatients with congestive heart failure. Can J Cardiol. 2004;20:697&#x2013;702.</Citation><ArticleIdList><ArticleId IdType="pubmed">15197422</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti K, Baker R, Grimshaw G. Diagnosis of patients with chronic heart failure in primary care: usefulness of history, examination, and investigations. Br J Gen Pract. 2000;50:50&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">10695070</ArticleId><ArticleId IdType="pmc">1313613</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev. 2006;11:95&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pubmed">16937029</ArticleId><ArticleId IdType="doi">10.1007/s10741-006-9481-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">27206819</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehw128</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:e895&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">35363499</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayes-Genis A, Aimo A, Jhund P, Richards M, de Boer RA, Arfsten H, Fabiani I, Lupon J, Anker SD, Gonzalez A, et al. Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022;24:1767&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">36073112</ArticleId><ArticleId IdType="doi">10.1002/ejhf.2675</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">34447992</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehab368</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledwidge M, Gallagher J, Conlon C, Tallon E, O&#x2019;Connell E, Dawkins I, Watson C, O&#x2019;Hanlon R, Bermingham M, Patle A, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA. 2013;310:66&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">23821090</ArticleId><ArticleId IdType="doi">10.1001/jama.2013.7588</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunwald E. Heart failure. JACC Heart Fail. 2013;1:1&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">24621794</ArticleId><ArticleId IdType="doi">10.1016/j.jchf.2012.10.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim NE, Januzzi JL Jr. Established and emerging roles of biomarkers in heart failure. Circ Res. 2018;123:614&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">30355136</ArticleId><ArticleId IdType="doi">10.1161/CIRCRESAHA.118.312706</ArticleId></ArticleIdList></Reference><Reference><Citation>James S, Barton D, O&#x2019;Connell E, Voon V, Murtagh G, Watson C, Murphy T, Prendiville B, Brennan D, Hensey M, et al. Life expectancy for community-based patients with heart failure from time of diagnosis. Int J Cardiol. 2015;178:268&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">25464268</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2014.09.131</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong AT, Leprevost FV, Avtonomov DM, Mellacheruvu D, Nesvizhskii AI. MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics. Nat Methods. 2017;14:513&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">28394336</ArticleId><ArticleId IdType="pmc">5409104</ArticleId><ArticleId IdType="doi">10.1038/nmeth.4256</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu F, Teo GC, Kong AT, Frohlich K, Li GX, Demichev V, Nesvizhskii AI. Analysis of DIA proteomics data using MSFragger-DIA and FragPipe computational platform. Nat Commun. 2023;14:4154.</Citation><ArticleIdList><ArticleId IdType="pubmed">37438352</ArticleId><ArticleId IdType="pmc">10338508</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-39869-5</ArticleId></ArticleIdList></Reference><Reference><Citation>da Veiga LF, Haynes SE, Avtonomov DM, Chang HY, Shanmugam AK, Mellacheruvu D, Kong AT, Nesvizhskii AI. Philosopher: a versatile toolkit for shotgun proteomics data analysis. Nat Methods. 2020;17:869&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-020-0912-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Demichev V, Messner CB, Vernardis SI, Lilley KS, Ralser M. DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput. Nat Methods. 2020;17:41&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">31768060</ArticleId><ArticleId IdType="doi">10.1038/s41592-019-0638-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberger G, Bludau I, Schmitt U, Heusel M, Hunter CL, Liu Y, MacCoss MJ, MacLean BX, Nesvizhskii AI, Pedrioli PGA, et al. Statistical control of peptide and protein error rates in large-scale targeted data-independent acquisition analyses. Nat Methods. 2017;14:921&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">28825704</ArticleId><ArticleId IdType="pmc">5581544</ArticleId><ArticleId IdType="doi">10.1038/nmeth.4398</ArticleId></ArticleIdList></Reference><Reference><Citation>Meier F, Brunner AD, Frank M, Ha A, Bludau I, Voytik E, Kaspar-Schoenefeld S, Lubeck M, Raether O, Bache N, et al. diaPASEF: parallel accumulation-serial fragmentation combined with data-independent acquisition. Nat Methods. 2020;17:1229&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257825</ArticleId><ArticleId IdType="doi">10.1038/s41592-020-00998-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.</Citation><ArticleIdList><ArticleId IdType="pubmed">25605792</ArticleId><ArticleId IdType="pmc">4402510</ArticleId><ArticleId IdType="doi">10.1093/nar/gkv007</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2:100141.</Citation><ArticleIdList><ArticleId IdType="pubmed">34557778</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang D, Chen M, Huang X, Zhang G, Zeng L, Zhang G, Wu S, Wang Y. SRplot: a free online platform for data visualization and graphing. PLoS ONE. 2023;18:e0294236.</Citation><ArticleIdList><ArticleId IdType="pubmed">37943830</ArticleId><ArticleId IdType="pmc">10635526</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0294236</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn M, Johnson K. Applied predictive modeling. Berlin: Springer; 2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4614-6849-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman JH, Roosen CB. An introduction to multivariate adaptive regression splines. Stat Methods Med Res. 1995;4:197&#x2013;217.</Citation><ArticleIdList><ArticleId IdType="pubmed">8548103</ArticleId><ArticleId IdType="doi">10.1177/096228029500400303</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright MN, Ziegler A (2015) Ranger: a fast implementation of random forests for high dimensional data in C++ and R. arXiv preprint arXiv:150804409</Citation></Reference><Reference><Citation>Gandhi PU, Chow SL, Rector TS, Krum H, Gaggin HK, McMurray JJ, Zile MR, Komajda M, McKelvie RS, Carson PE, et al. Prognostic value of insulin-like growth factor-binding protein 7 in patients with heart failure and preserved ejection fraction. J Card Fail. 2017;23:20&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27317843</ArticleId><ArticleId IdType="doi">10.1016/j.cardfail.2016.06.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Januzzi JL Jr, Packer M, Claggett B, Liu J, Shah AM, Zile MR, Pieske B, Voors A, Gandhi PU, Prescott MF, et al. IGFBP7 (insulin-like growth factor-binding protein-7) and neprilysin inhibition in patients with heart failure. Circ Heart Fail. 2018;11:e005133.</Citation><ArticleIdList><ArticleId IdType="pubmed">30354399</ArticleId><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.118.005133</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbah MS, Fayyaz AU, de Denus S, Felker GM, Borlaug BA, Dasari S, Carter RE, Redfield MM. Obese-inflammatory phenotypes in heart failure with preserved ejection fraction. Circ Heart Fail. 2020;13:e006414.</Citation><ArticleIdList><ArticleId IdType="pubmed">32809874</ArticleId><ArticleId IdType="pmc">7439286</ArticleId><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.119.006414</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad F, Ataam JA, Amsallem M, Cauwenberghs N, Kuznetsova T, Rosenberg-Hasson Y, Zamanian RT, Karakikes I, Horne BD, Muhlestein JB, et al. Insulin growth factor phenotypes in heart failure with preserved ejection fraction, an INSPIRE registry and CATHGEN study. J Card Fail. 2022;28:935&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">34979242</ArticleId><ArticleId IdType="doi">10.1016/j.cardfail.2021.12.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshak ES, Maruyama K, Iso H, Tamakoshi A. The prospective association between plasma concentrations of cellular growth factors and risk of heart failure mortality in Japanese population. J Epidemiol. 2019;29:104&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30078811</ArticleId><ArticleId IdType="pmc">6375814</ArticleId><ArticleId IdType="doi">10.2188/jea.JE20170123</ArticleId></ArticleIdList></Reference><Reference><Citation>Okura Y, Brink M, Zahid AA, Anwar A, Delafontaine P. Decreased expression of insulin-like growth factor-1 and apoptosis of vascular smooth muscle cells in human atherosclerotic plaque. J Mol Cell Cardiol. 2001;33:1777&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">11603921</ArticleId><ArticleId IdType="doi">10.1006/jmcc.2001.1441</ArticleId></ArticleIdList></Reference><Reference><Citation>Frystyk J, Ledet T, Moller N, Flyvbjerg A, Orskov H. Cardiovascular disease and insulin-like growth factor I. Circulation. 2002;106:893&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186788</ArticleId><ArticleId IdType="doi">10.1161/01.CIR.0000030720.29247.9F</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz Del Moral S, Benaouicha M, Munoz-Chapuli R, Carmona R (2021) The insulin-like growth factor signalling pathway in cardiac development and regeneration. Int J Mol Sci 23</Citation></Reference><Reference><Citation>Vogt AM, Htun P, Kluge A, Zimmermann R, Schaper W. Insulin-like growth factor-II delays myocardial infarction in experimental coronary artery occlusion. Cardiovasc Res. 1997;33:469&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">9074712</ArticleId><ArticleId IdType="doi">10.1016/S0008-6363(96)00212-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39:2780&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">29905796</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehy301</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermann D, Lindner D, Kasner M, Zietsch C, Savvatis K, Escher F, von Schlippenbach J, Skurk C, Steendijk P, Riad A, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011;4:44&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">21075869</ArticleId><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.109.931451</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew DT, Peigh G, Lima JAC, Bielinski SJ, Larson NB, Allison MA, Shah SJ, Patel RB. Associations of circulating vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 with long-term cardiac function. J Am Heart Assoc. 2024;13:e032213.</Citation><ArticleIdList><ArticleId IdType="pubmed">38497480</ArticleId><ArticleId IdType="pmc">11009988</ArticleId><ArticleId IdType="doi">10.1161/JAHA.123.032213</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit G, Blair J, Ozcan C. Plasma proteomic analysis of association between atrial fibrillation, coronary microvascular disease and heart failure. Am J Cardiovasc Dis. 2022;12:81&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">35600285</ArticleId><ArticleId IdType="pmc">9123414</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah AM, Myhre PL, Arthur V, Dorbala P, Rasheed H, Buckley LF, Claggett B, Liu G, Ma J, Nguyen NQ, et al. Large scale plasma proteomics identifies novel proteins and protein networks associated with heart failure development. Nat Commun. 2024;15:528.</Citation><ArticleIdList><ArticleId IdType="pubmed">38225249</ArticleId><ArticleId IdType="pmc">10789789</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-44680-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Klimentova J, Rehulka P, Stulik J, Vozandychova V, Rehulkova H, Jurcova I, Lazarova M, Aiglova R, Dokoupil J, Hrecko J, Pudil R. Proteomic profiling of dilated cardiomyopathy plasma samples horizontal line searching for biomarkers with potential to predict the outcome of therapy. J Proteome Res. 2024;23:971&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">38363107</ArticleId><ArticleId IdType="pmc">10913098</ArticleId><ArticleId IdType="doi">10.1021/acs.jproteome.3c00691</ArticleId></ArticleIdList></Reference><Reference><Citation>Park JJ, Yoon M, Cho HW, Cho HJ, Kim KH, Yang DH, Yoo BS, Kang SM, Baek SH, Jeon ES, et al. C-reactive protein and statins in heart failure with reduced and preserved ejection fraction. Front Cardiovasc Med. 2022;9:1064967.</Citation><ArticleIdList><ArticleId IdType="pubmed">36620625</ArticleId><ArticleId IdType="pmc">9816146</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2022.1064967</ArticleId></ArticleIdList></Reference><Reference><Citation>Burger PM, Koudstaal S, Mosterd A, Fiolet ATL, Teraa M, van der Meer MG, Cramer MJ, Visseren FLJ, Ridker PM, Dorresteijn JAN. Group U-Ss: C-reactive protein and risk of incident heart failure in patients with cardiovascular disease. J Am Coll Cardiol. 2023;82:414&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">37495278</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2023.05.035</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer RA, Nayor M, deFilippi CR, Enserro D, Bhambhani V, Kizer JR, Blaha MJ, Brouwers FP, Cushman M, Lima JAC, et al. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA Cardiol. 2018;3:215&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">29322198</ArticleId><ArticleId IdType="pmc">5862778</ArticleId><ArticleId IdType="doi">10.1001/jamacardio.2017.4987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartupee J, Mann DL. Positioning of inflammatory biomarkers in the heart failure landscape. J Cardiovasc Transl Res. 2013;6:485&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">23666808</ArticleId><ArticleId IdType="doi">10.1007/s12265-013-9467-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Askevold ET, Nymo S, Ueland T, Gravning J, Wergeland R, Kjekshus J, Yndestad A, Cleland JG, McMurray JJ, Aukrust P, Gullestad L. Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circ Heart Fail. 2013;6:91&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23230311</ArticleId><ArticleId IdType="doi">10.1161/CIRCHEARTFAILURE.112.972653</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B, Mann DL, Deswal A. Biomarkers of inflammation in heart failure. Heart Fail Rev. 2010;15:331&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">19363700</ArticleId><ArticleId IdType="doi">10.1007/s10741-009-9140-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Anholt RR. Olfactomedin proteins: central players in development and disease. Front Cell Dev Biol. 2014;2:6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25364714</ArticleId><ArticleId IdType="pmc">4206993</ArticleId><ArticleId IdType="doi">10.3389/fcell.2014.00006</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvandi Z, Bischoff J. Endothelial-mesenchymal transition in cardiovascular disease. Arterioscler Thromb Vasc Biol. 2021;41:2357&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">34196216</ArticleId><ArticleId IdType="pmc">8387428</ArticleId><ArticleId IdType="doi">10.1161/ATVBAHA.121.313788</ArticleId></ArticleIdList></Reference><Reference><Citation>Lencinas A, Chhun DC, Dan KP, Ross KD, Hoover EA, Antin PB, Runyan RB. Olfactomedin-1 activity identifies a cell invasion checkpoint during epithelial-mesenchymal transition in the chick embryonic heart. Dis Model Mech. 2013;6:632&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">23264563</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong PK, Lee H, Zhou J, Liu SC, Loh MC, Wang TT, Chan SP, Smoot DT, Ashktorab H, So JB, et al. ITIH3 is a potential biomarker for early detection of gastric cancer. J Proteome Res. 2010;9:3671&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20515073</ArticleId><ArticleId IdType="pmc">3760204</ArticleId><ArticleId IdType="doi">10.1021/pr100192h</ArticleId></ArticleIdList></Reference><Reference><Citation>Talari NK, Mattam U, Kaminska D, Sotomayor-Rodriguez I, Rahman AP, Peterfy M, Pajukanta P, Pihlajamaki J, Chella Krishnan K (2024) Hepatokine ITIH3 protects against hepatic steatosis by downregulating mitochondrial bioenergetics and de novo lipogenesis. iScience 27:109709</Citation></Reference><Reference><Citation>Takeuchi H, Tomita H, Taki Y, Kikuchi Y, Ono Tanaka C, Yu Z, Matsudaira I, Nouchi R, Imanishi T, Kawashima R. A psychiatric disorder risk polymorphism of ITIH3 is associated with multiple neuroimaging phenotypes in young healthy adults. Psychiatry Clin Neurosci. 2022;76:271&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">35261121</ArticleId><ArticleId IdType="doi">10.1111/pcn.13347</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostrominski JW, DeFilippis EM, Bansal K, Riello RJ 3rd, Bozkurt B, Heidenreich PA, Vaduganathan M. Contemporary American and European Guidelines for Heart Failure Management: JACC: Heart Failure Guideline Comparison. JACC Heart Fail. 2024;12:810&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">38583167</ArticleId><ArticleId IdType="doi">10.1016/j.jchf.2024.02.020</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, et al. 2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44:3627&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622666</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehad195</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>